Summary of Clinical Use

This antibody is being investigated as a neuroprotector for patients with Alzheimer's disease (AD) [3-4]. The Jan 23 (2014) issue of the New England Journal of Medicine carries an article by Doody et al. reporting the results of two phase 3 clinical trials of solanezumab in patients with mild-moderate AD. In these trials solanezumab failed to cause any change in patients' levels of cognition or functional ability [1]. It has been suggested that Aβ binding drugs such as solanezumab (and bapineuzumab) may be more useful as preventative treatments for patients at risk of developing AD with the aim of preventing Aβ plaque formation, as treatment post-plaque formation appears to be too late. Phase 3 trial NCT01900665 is under way focussing on patients with mild AD, and Phase 3 NCT02760602 is focussing on prodromal patients, where it is hoped there is greater potential to show efficacy.

Mechanism Of Action and Pharmacodynamic Effects

It is hypothesised that the antibody will sequester circulating Aβ, thereby reducing amyloid load, with the potential to slow the development of amyloid plaques.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT01900665	Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo	Phase 3 Interventional	Eli Lilly and Company
NCT02760602	A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease	Phase 3 Interventional	Eli Lilly and Company